1. Worldwide experience with biosimilar development;McCamish;mAbs,2011
2. Guidance on similar medicinal products containing recombinant granulocyte-colony stimulating factor. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues guidance on similar medicinal products containing recombinant granulocyte-colony stimulating factor, EMEA/CHMP/BMWP/31329/2005.
3. Food and Drug Administration, Guidance for Industry. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product April 2015.
4. G-CSF and GM-CSF in neutropenia;Mehta;J Immunol,2015
5. Optimizing dose and scheduling of filgrastim (granulocyte colony stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers;Grigg;Blood,1995